Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13466-13476
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13466
Figure 3
Figure 3 Proteomic markers for colitis-associated cancer risk in patients with both ulcerative colitis and Crohn’s disease. After analyzing signaling pathways from label-free quantitative analysis, four important proteome biomarkers were identified: proteoglycan 2 (PRG2), S100 calcium binding protein A8 (S100A8), ribosomal protein L18 (RPL18), and UDP-glucose dehydrogenase (UGDH), all of which showed fold changes. Validation is ongoing to investigate these biomarkers for predicting colitis-associated cancer risk in patients with inflammatory bowel disease. UC: Ulcerative colitis; CD: Crohn’s disease.